Drug Profile


Alternative Names: APD-125

Latest Information Update: 01 Sep 2016

Price : $50

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; Axovant Sciences
  • Class Sleep disorder therapies; Small molecules
  • Mechanism of Action Serotonin 2A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lewy body disease
  • Discontinued Insomnia

Most Recent Events

  • 01 Aug 2016 Axovant Sciences initiates a phase-II clinical trial in Lewy body disease (In adults, In the elderly) in USA (NCT02871427)
  • 01 Aug 2016 Phase-II clinical trials in Lewy body disease (In children, In adolescents) in USA (PO) (NCT02871427)
  • 30 Mar 2016 Arena Pharmaceuticals has patent protection for Nelotanserin in 76 jurisdictions, including the US, Japan, China, Germany, France, Italy, the United Kingdom, Spain, Canada, Russia, India, Australia and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top